Understanding mutation hotspots for the SARS-CoV-2 spike protein using Shannon Entropy and K-means clustering.

The SARS-CoV-2 virus like many other viruses has transformed in a continual manner to give rise to new variants by means of mutations commonly through substitutions and indels. These mutations in some cases can give the virus a survival advantage making the mutants dangerous. In general, laboratory investigation must be carried to determine whether the new variants have any characteristics that can make them more lethal and contagious.

Use of erythromycin for nonsurgical female sterilization in West Bengal, India: a study of 790 cases.

Objective: Determine if erythromycin is an effective agent for achieving occlusion of the Fallopian tube for nonsurgical female sterilization.

Methods: Two studies of 100 healthy volunteers requesting sterilization were planned, one in Julpia Andhermanik and the other in Kolkata (Calcutta). A readily available marketed tablet preparation containing 500 mg of the estolate salt of erythromycin was used for the trial.

Comparison of the efficacy of intrauterine diclofenac and ibuprofen pellets as adjuvants to quinacrine nonsurgical female sterilization.

To investigate relative efficacy of intrauterine diclofenac and ibuprofen as adjuvants to intrauterine quinacrine for nonsurgical sterilization, a total of 900 women were systematically allocated to 2 monthly insertions of pellets of diclofenac (75 mg) or ibuprofen (55.5 mg) as adjuvants to intrauterine quinacrine (216 mg) in a rural private practice in West Bengal, India. All women were prescribed oral contraceptives for three months from first insertion.

A potential single insertion protocol for quinacrine pellet non-surgical female sterilization.

Two preliminary single-insertion clinical trials of the quinacrine pellet method of non-surgical female sterilization were compared. Both trials used transcervical application of quinacrine, 252 mg, and diclofenac, 75 mg, as pellets. In the first trial (21 April 1992 to 17 February 1993), 58 women received oral contraceptives for three months.